Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

I’ve no history of nosebleeds, but over the past five weeks, I’ve had five. The first three times, the bleeding stopped after ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

New technology and drugs are transforming how doctors detect and treat silent liver disease MASLD before it leads to liver ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including American Express Co. (AXP), NextEra ...

The US regulator has cleared Madrigal’s oral THR β-selective agonist Rezdiffra (resmetirom) for adults with MASH – also known as non-alcoholic steatohepatitis (NASH) – who have moderate to ...

Analysts have suggested that the benefit of semaglutide is similar to that seen with Madrigal Pharma's Rezdiffra (resmetirom), currently the only FDA-approved therapy for MASH, which is also known ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a variably defined ...